Matches in SemOpenAlex for { <https://semopenalex.org/work/W2325596265> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2325596265 endingPage "P63" @default.
- W2325596265 startingPage "P63" @default.
- W2325596265 abstract "BACKGROUND Sitagliptin (MK-0431), an orally active, potent and selective DPP-IV inhibitor being developed for Type 2 diabetes mellitus, is a substrate for p-glycoprotein (Pgp). High dose cyclosporine A (CSA) was used as a probe Pgp inhibitor to evaluate the effect of potent Pgp inhibition on sitagliptin PK. METHODS 8 healthy young men received Treatments A (single oral 600 mg dose of CSA[NEORAL™] with a single 100 mg oral sitagliptin dose) and B (single oral 100 mg sitagliptin dose alone) in an open-label, randomized, 2-period, crossover study, separated by a 2-week washout. Pre-specified bounds of[0.50, 2.00] were used for AUC GMR whether any alterations in MK-0431 PK was clinically meaningful. RESULTS Sitagliptin with or without CSA was generally well tolerated. Sitagliptin AUC0-∞ GMR (1.29) with 90% CI[1.24, 1.34], and Cmax GMR (1.68) with 90% CI[1.35, 2.08] indicated modest effects by CSA and unlikely to be clinically relevant. There were no meaningful differences in CLr, apparent t1/2 or C24hr. CONCLUSIONS This study with high dose CSA confirmed that sitagliptin was a substrate for Pgp. Co-administration of CSA with sitagliptin only modestly increased Cmax of sitagliptin without a meaningful effect on overall exposure. Given only modest alterations in PK (i.e., on Cmax) with a highly potent Pgp inhibitor, the magnitude of changes in sitagliptin PK with other medications that are Pgp inhibitors, albeit less potent ones, is unlikely to be clinically meaningful. Clinical Pharmacology & Therapeutics (2005) 79, P63–P63; doi: 10.1016/j.clpt.2005.12.225" @default.
- W2325596265 created "2016-06-24" @default.
- W2325596265 creator A5003619733 @default.
- W2325596265 creator A5021441570 @default.
- W2325596265 creator A5029691123 @default.
- W2325596265 creator A5048351488 @default.
- W2325596265 creator A5048879060 @default.
- W2325596265 creator A5059590015 @default.
- W2325596265 creator A5061427649 @default.
- W2325596265 creator A5063665467 @default.
- W2325596265 creator A5073817158 @default.
- W2325596265 creator A5076907136 @default.
- W2325596265 date "2006-02-01" @default.
- W2325596265 modified "2023-09-27" @default.
- W2325596265 title "PIII-17Effect of a single cyclosporine a (NEORAL™) dose on the single-dose pharmacokinetics (PK) of sitagliptin (MK-0431), a dipeptidyl peptidase-IV inhibitor (DPP-IV), in healthy male subjects" @default.
- W2325596265 doi "https://doi.org/10.1016/j.clpt.2005.12.225" @default.
- W2325596265 hasPublicationYear "2006" @default.
- W2325596265 type Work @default.
- W2325596265 sameAs 2325596265 @default.
- W2325596265 citedByCount "2" @default.
- W2325596265 crossrefType "journal-article" @default.
- W2325596265 hasAuthorship W2325596265A5003619733 @default.
- W2325596265 hasAuthorship W2325596265A5021441570 @default.
- W2325596265 hasAuthorship W2325596265A5029691123 @default.
- W2325596265 hasAuthorship W2325596265A5048351488 @default.
- W2325596265 hasAuthorship W2325596265A5048879060 @default.
- W2325596265 hasAuthorship W2325596265A5059590015 @default.
- W2325596265 hasAuthorship W2325596265A5061427649 @default.
- W2325596265 hasAuthorship W2325596265A5063665467 @default.
- W2325596265 hasAuthorship W2325596265A5073817158 @default.
- W2325596265 hasAuthorship W2325596265A5076907136 @default.
- W2325596265 hasConcept C112705442 @default.
- W2325596265 hasConcept C126322002 @default.
- W2325596265 hasConcept C134018914 @default.
- W2325596265 hasConcept C156490143 @default.
- W2325596265 hasConcept C22979827 @default.
- W2325596265 hasConcept C2777180221 @default.
- W2325596265 hasConcept C2778763485 @default.
- W2325596265 hasConcept C2779284873 @default.
- W2325596265 hasConcept C2910260750 @default.
- W2325596265 hasConcept C555293320 @default.
- W2325596265 hasConcept C71924100 @default.
- W2325596265 hasConcept C98274493 @default.
- W2325596265 hasConceptScore W2325596265C112705442 @default.
- W2325596265 hasConceptScore W2325596265C126322002 @default.
- W2325596265 hasConceptScore W2325596265C134018914 @default.
- W2325596265 hasConceptScore W2325596265C156490143 @default.
- W2325596265 hasConceptScore W2325596265C22979827 @default.
- W2325596265 hasConceptScore W2325596265C2777180221 @default.
- W2325596265 hasConceptScore W2325596265C2778763485 @default.
- W2325596265 hasConceptScore W2325596265C2779284873 @default.
- W2325596265 hasConceptScore W2325596265C2910260750 @default.
- W2325596265 hasConceptScore W2325596265C555293320 @default.
- W2325596265 hasConceptScore W2325596265C71924100 @default.
- W2325596265 hasConceptScore W2325596265C98274493 @default.
- W2325596265 hasIssue "2" @default.
- W2325596265 hasLocation W23255962651 @default.
- W2325596265 hasOpenAccess W2325596265 @default.
- W2325596265 hasPrimaryLocation W23255962651 @default.
- W2325596265 hasRelatedWork W1526529090 @default.
- W2325596265 hasRelatedWork W1535694155 @default.
- W2325596265 hasRelatedWork W2030861315 @default.
- W2325596265 hasRelatedWork W2048453661 @default.
- W2325596265 hasRelatedWork W2113431531 @default.
- W2325596265 hasRelatedWork W2147698512 @default.
- W2325596265 hasRelatedWork W2324643450 @default.
- W2325596265 hasRelatedWork W2608558167 @default.
- W2325596265 hasRelatedWork W2797646286 @default.
- W2325596265 hasRelatedWork W3026628716 @default.
- W2325596265 hasVolume "79" @default.
- W2325596265 isParatext "false" @default.
- W2325596265 isRetracted "false" @default.
- W2325596265 magId "2325596265" @default.
- W2325596265 workType "article" @default.